Silk Road Medical (SILK) Scheduled to Post Quarterly Earnings on Tuesday

Silk Road Medical (NASDAQ:SILK) will issue its quarterly earnings data after the market closes on Tuesday, April 30th. Analysts expect the company to announce earnings of ($0.40) per share for the quarter. Silk Road Medical has set its FY 2024 guidance at EPS.Parties interested in registering for the company’s conference call can do so using this link.

Silk Road Medical (NASDAQ:SILK) last issued its earnings results on Wednesday, February 28th. The company reported ($0.33) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.07. The company had revenue of $47.27 million during the quarter, compared to the consensus estimate of $42.23 million. Silk Road Medical had a negative net margin of 31.70% and a negative return on equity of 36.38%. On average, analysts expect Silk Road Medical to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Silk Road Medical Trading Up 0.8 %

Shares of Silk Road Medical stock opened at $17.80 on Friday. The company has a market capitalization of $697.23 million, a P/E ratio of -12.36 and a beta of 1.48. The company has a debt-to-equity ratio of 0.50, a quick ratio of 6.97 and a current ratio of 7.95. The company has a fifty day moving average of $17.52 and a 200 day moving average of $13.23. Silk Road Medical has a fifty-two week low of $6.08 and a fifty-two week high of $45.08.

Analysts Set New Price Targets

Several research analysts have commented on the stock. JPMorgan Chase & Co. increased their price objective on shares of Silk Road Medical from $10.00 to $19.00 and gave the company a “neutral” rating in a report on Thursday, February 29th. Stifel Nicolaus increased their price objective on shares of Silk Road Medical from $20.00 to $23.00 and gave the company a “buy” rating in a report on Thursday, February 29th. Argus raised shares of Silk Road Medical from a “hold” rating to a “buy” rating and set a $24.00 price objective for the company in a report on Thursday, March 7th. Lake Street Capital assumed coverage on shares of Silk Road Medical in a report on Wednesday, January 3rd. They set a “buy” rating and a $20.00 price objective for the company. Finally, Piper Sandler increased their price objective on shares of Silk Road Medical from $11.00 to $18.00 and gave the company a “neutral” rating in a report on Thursday, February 29th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, Silk Road Medical currently has an average rating of “Hold” and a consensus price target of $22.18.

Insider Buying and Selling

In other news, Director Kevin J. Ballinger acquired 11,700 shares of Silk Road Medical stock in a transaction that occurred on Tuesday, March 5th. The shares were bought at an average cost of $16.99 per share, with a total value of $198,783.00. Following the transaction, the director now directly owns 17,807 shares of the company’s stock, valued at approximately $302,540.93. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, Director Kevin J. Ballinger acquired 11,700 shares of Silk Road Medical stock in a transaction that occurred on Tuesday, March 5th. The shares were bought at an average cost of $16.99 per share, with a total value of $198,783.00. Following the transaction, the director now directly owns 17,807 shares of the company’s stock, valued at approximately $302,540.93. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Andrew S. Davis sold 5,481 shares of the stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $17.17, for a total transaction of $94,108.77. Following the completion of the sale, the insider now directly owns 287,773 shares in the company, valued at $4,941,062.41. The disclosure for this sale can be found here. Insiders have sold 20,457 shares of company stock valued at $351,247 in the last ninety days. 6.70% of the stock is owned by company insiders.

About Silk Road Medical

Silk Road Medical, Inc operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization (TCAR). Its products comprise ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and establish temporary blood flow reversal; ENROUTE Transcarotid Stent System for transcarotid access; ENHANCE Transcarotid Peripheral Access Kit, which is used to gain initial access to the common carotid artery; ENROUTE 0.014 Guidewire for atraumatic vessel navigation and target lesion crossing for delivery of interventional devices; and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter, a transcarotid rapid exchange balloon for the TCAR procedure.